Stabilized nanoparticle formulations of camptotheca derivatives

• US 20040009229A1
• Filed: 06/05/2003
• Published: 01/15/2004
• Est. Priority Date: 01/05/2000
• Status: Abandoned Application

• Current Assignee: Imarx Therapeutics, Inc. (Sycamore Entertainment Group, Inc.)
• Original Assignee: Imarx Therapeutics, Inc. (Sycamore Entertainment Group, Inc.)
• Inventors: Unger, Evan Charles, LaBell, Rachel Yvonne, Romanowski, Marek J., Pigman, Elizabeth Anne, Zutshi, Reena, Ramaswami, VaradaRajan
• Application Number:
  US10/457,068
• Publication Number:
  US 20040009229A1
• Time in Patent Office: Days
• US Class Current: 424/486
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 47/6907 the form being a microemulsion, nanoemulsion or micelle
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence
• CPC Class Codes: A61K 9/5146 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
• CPC Class Codes: A61K 9/5192 Processes
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Pharmaceutical formulations are provided that increase the systemic bioavailability of camptotheca derivatives; preferably, the camptothecin derivative is 7-ethyl-10-hydroxyl camptothecin, SN-38. The drug is complexed with a stabilizing agent, but is not covalently bound thereto. Anionic or neutral lipids and/or polymers are used as the stabilizing agent, and secondary stabilizing agents and/or other excipients may be incorporated into the formulation as well. Therapeutic methods are also provided, wherein a formulation of the invention is administered to a patient to treat a condition, disorder, or disease that is responsive to camptothecin derivatives. Generally, administration is oral or parenteral.

Claims

1. A pharmaceutical formulation comprising:

a camptothecin analog;

a stabilizing agent that stabilizes the camptothecin analog but does not covalently bind thereto;

an optional targeting ligand; and

an optional excipient.

2. The formulation of claim 1, wherein the stabilizing agent comprises a polymer, a lipid, a polymer-lipid conjugate, or a combination thereof.

3. The formulation of claim 2, wherein the stabilizing agent is a polymer.

4. The formulation of claim 3, wherein the polymer is selected from linear and branched structures.

5. The formulation of claim 4, wherein the polymer is a block copolymer.

6. The formulation of claim 5, wherein the polymer is a branched block copolymer selected from polyethylene glycol-polypropylene oxide, polyethylene glycol-polylactide, polyethylene glycol-polylactide-coglycolide, and polyethylene glycol-b-polycaprolactone copolymers.

7. The formulation of claim 5, wherein the polymer is a branched block copolymer having a central core and about 3 to 12 arms radiating therefrom.

8. The formulation of claim 7, wherein each arms comprises a block copolymer with an inner, more hydrophobic block and an outer, more hydrophilic block.

9. The formulation of claim 7, wherein each arms comprises a block copolymer with an inner, more hydrophilic block and an outer, more hydrophobic block.

10. The formulation of claim 3, wherein the polymer is selected from polyethylene glycol, polyglycolide, polyvinyl alcohol, polyvinyl pyrrolidone, polylactide, poly(lactide-co-glycolide), polycaprolactone, polysorbate, polyethylene oxide, polypropylene oxide, poly(ethylene oxide-co-propylene oxide), poloxamer, poloxamine, poly(oxyethylated) glycerol, poly(oxyethylated) sorbitol, poly(oxyethylated) glucose, and derivatives, mixtures, and copolymers thereof.

11. The formulation of claim 3, wherein the polymer is poloxamer.

12. The formulation of claim 3, wherein the polymer is poloxamine.

13. The formulation of claim 3, wherein the polymer is selected from the group consisting of a polyethylene glycol and polypropylene glycol and copolymers thereof.

14. The formulation of claim 13, wherein the polymer is selected from branched polyethylene glycol, linear polyethylene glycol, and combinations thereof, and is optionally covalently bound to at least one phospholipid moiety.

15. The formulation of claim 13, wherein the polyethylene glycol is functionalized to contain at least one sulfhydryl, amino, lower alkoxy, carboxylate, or phosphonate moiety.

16. The formulation of claim 13, wherein the polyethylene glycol or polypropylene glycol contains a hydrolyzable linkage.

17. The formulation of claim 13, wherein the polyethylene glycol is bonded to a phospholipid moiety.

18. The formulation of claim 17, wherein the polyethylene glycol ranges in size from about 350 to 7000 daltons.

19. The formulation of claim 18, wherein the polyethylene glycol ranges in size from about 750 to 5000 daltons.

20. The formulation of claim 3, wherein the polymer is a polysorbate.

21. The formulation of claim 2, wherein the stabilizing agent is a lipid with a lipid to drug weight ratio less than 5:

1

22. The formulation of claim 21, wherein the lipid to drug ratio is less than 3:

1.

23. The formulation of claim 21, wherein the lipid is selected from natural phospholipids, chemically and enzymatically modified phospholipids, and synthetic phospholipids.

24. The formulation of claim 23, wherein the lipid is a natural phospholipid.

25. The formulation of claim 23, wherein the lipid is a synthetic phospholipid.

26. The formulation of claim 23, wherein the lipid is a diacyl phospholipid.

27. The formulation of claim 26, wherein the lipid is selected from diacyl phosphatidylcholines, diacyl phosphatidylethanolamines, diacyl phosphatidylserines, diacyl phosphatidylinositols, diacyl phosphatidic acids, phosphorylated diacylglycerides, and combinations thereof.

28. The formulation of claim 27, wherein the lipid is a phosphorylated diacylglyceride.

29. The formulation of claim 28, wherein the phosphorylated diacylglyceride is selected from dioleoyl phosphatidylglycerol, palmitoyloleyl phosphatidylglycerol, and combinations thereof.

30. The formulation of claim 27, wherein the lipid is a diacyl phosphatidylcholine.

31. The formulation of claim 30, wherein the diacyl phosphatidylcholine is selected from palmitoyloleoyl phosphatidylcholine, dioleoyl phosphatidylcholine, dilauroyl phosphatidylcholine, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, distearoyl phosphatidylcholine, and combinations thereof.

32. The formulation of claim 27, wherein the lipid is a diacyl phosphatidylethanolamine.

33. The formulation of claim 32, wherein the diacyl phosphatidylethanolamine is selected from dipalmitoyl phosphatidylethanolamine, 1-palmitoyl-2-oleoylphosphatidylethanolamine, dioleylphosphatidylethanolamine, and combinations thereof.

34. The formulation of claim 1, wherein the stabilizing agent is a polymer-lipid conjugate.

35. The method of claim 34 wherein the polymer is polyethylene glycol and the lipid is selected from phospholipids and fatty acids.

36. The formulation of claim 1, wherein the optional excipient is present.

37. The formulation of claim 36, wherein the excipient is selected from polyhydroxyalcohols, saccharides, liquid polyethylene glycols, propylene glycol, glycerol, ethyl alcohol, and combinations thereof.

38. The formulation of claim 1, wherein the camptothecin analog has the structure of formula (I)

39. The formulation of claim 38, wherein R¹, R², R³, R⁴, and R⁵ are independently selected from the group consisting of H, C_1-6 alkyl, C_1-6 alkoxy, acyloxy, hydroxyl, sulfhydryl, acyl, halo, amido, C_1-6 alkylamido, amino, nitro, and cyano.

40. The formulation of claim 39, wherein R¹ is C_1-6 alkyl, and R², R³, R⁴, and R⁵ are independently selected from the group consisting of H, C_1-6 alkyl, C_1-6 alkoxy, acyloxy, hydroxyl, sulfhydryl, acyl, halo, amido, C_1-6 alkylamido, amino, nitro, and cyano.

41. The formulation of claim 40, wherein R³ is hydroxyl, and R², R⁴, and R⁵ are independently selected from the group consisting of H, C_1-6 alkyl, C_1-6 alkoxy, acyloxy, hydroxyl, sulfhydryl, acyl, halo, amido, C_1-6 alkylamido, amino, nitro, and cyano.

42. The formulation of claim 39, wherein R³ is hydroxyl, and R¹, R², R⁴, and R⁵ are independently selected from the group consisting of H, C_1-6 alkyl, C_1-6 alkoxy, acyloxy, hydroxyl, sulfhydryl, acyl, halo, amido, C_1-6 alkylamido, amino, nitro, and cyano.

43. The formulation of claim 38, wherein R², R⁴, and R⁵ are H, such that the camptothecin analog has the structure of formula (II)

44. The formulation of claim 43, wherein R¹ is C_1-6 alkyl and R³ is hydroxyl, sulfhydryl, or amino.

45. The formulation of claim 44, wherein R³ is hydroxyl.

46. The formulation of claim 45, wherein the camptothecin analog is 7-ethyl-10-hydroxyl camptothecin.

47. The formulation of claim 1, wherein the formulation is in the form of an aqueous suspension and further comprises an aqueous vehicle.

48. The formulation of claim 47, wherein the aqueous vehicle is water, an isotonic diluent, or a buffer solution.

49. The formulation of claim 1, wherein the formulation is particulate.

50. The formulation of claim 49, wherein the formulation is comprised of particles that have an average size in the range of about 1-1000 nm.

51. The formulation of claim 50, wherein the average size of the particles is in the range of about 50-800 nm.

52. The formulation of claim 47, wherein the aqueous suspension further comprises an acoustically active gas.

62. A method for delivering a drug to a mammalian individual to achieve a desired therapeutic effect, comprising administering to the individual a therapeutically effective amount of the formulation of claim 1.

63. The method of claim 62, wherein administration is parenteral.

64. The method of claim 63, wherein administration is intravenous.

65. The method of claim 62, wherein administration is oral.

53. A method for making a nanoparticulate formulation of a camptothecin analog, comprising:

(a) admixing, in a solvent, a camptothecin analog and a stabilizing agent that stabilizes the camptothecin analog but does not covalently bond thereto;

(b) removing the solvent in a manner effective to provide a dry formulation of the camptothecin analog; and

(c) rehydrating the dry formulation to provide the nanoparticulate formulation.

54. The method of claim 53, wherein the solvent is removed by lyophilization.

55. The method of claim 53, wherein the solvent is removed by spray drying.

56. The method of claim 53, wherein (b) comprises removing the solvent by rotary evaporation, thereby providing an agglomerated intermediate product, and wherein the method further comprises (b′

) deagglomerating the intermediate product using a procedure effective to provide the nanoparticulate formulation of the camptothecin analog.

57. The method of claim 53, wherein the solute is a supercritical fluid, such as liquid carbon dioxide.

58. The method of claim 53, wherein prior to (a), the step is added of dissolving the camptothecin analog in a first solvent to form a first solution and dissolving the stabilizing agent in a second solvent to form a second solution, and (a) comprises admixing the first solution with second solution.

59. The method of claim 53, wherein an additional component of the stabilizing agent is added during step (c).

60. The method of claim 59, wherein the additional component of the stabilizing agent is a poloxamer and/or a poloxamine.

61. A nanoparticulate formulation of a camptothecin analog prepared according to the method of claim 53.

66. A method for treating an individual suffering from cancer, comprising administering to the individual a spatially stabilized matrix formulation of:

(a) drug-containing particles comprised of (i) a stabilizing agent, (ii) a camptothecin analog that is entrapped by but not covalently bound to the stabilizing agent, optionally (iii) a targeting ligand, and optionally (iv) an excipient selected from the group consisting of saccharides, liquid polyethylene glycols, propylene glycol, glycerol, ethyl alcohol, and combinations thereof, in

(b) an aqueous vehicle suitable for parenteral drug administration.

67. The method of claim 66, wherein the formulation is administered parenterally and the vehicle is suitable for parenteral administration.